Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — Shareholder Meeting (November 2021)
22 slides from Monash Ivf's shareholder meeting presentation, Nov 19, 2021
Slide 1: Leading the future of reproductive care
Leading the future of reproductive care 2021 Annual General Meeting Ne Monash IVF Group |_| Leading the future of reproductive care
Slide 2: Disclaimer
Disclaimer The presentation has been prepared by Monash VF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF's activities as at the date of this presentation. The information does not purpor
Slide 3: Chairman's Address
Chairman’s Address Mr. Richard Davis
Slide 4: Board of Directors
IN @ Monash IVF Group Board of Directors CO Sas wa SS Ke Richard Davis Neil Broekhuizen Josef Ozyzewski Richard Henshaw - . y [ey S \ | . Zita Peach Catherine West Michael Knaap Malik Jainudeen Company Secretary 4 2021 Annual General Meeting
Slide 5: Voting instructions
Voting instructions + Get a Voting Card Voting Card 1. Click the Get a Voting Card box on your screen 2. Enter your Shareholder or Proxy Details FullVote Partial vote and click Submit Details and Vote 3. When the Voting Card pops up, select either Eull Vote or Partial Vote 4. Select your voting pref
Slide 6: How to Ask a Question
How to Ask a Question t? Click the Ask a Question box on your Ask a Question screen 2. Select the Item of Business your question relates to Type your question in the space provided* 4. Click Submit Question Gvsstio If you require Assistance, please call Link Market Services on 1800 990 363 *Please n
Slide 7: Non IFRS measure. Refer to page 29 of 2021 Annual Report for reconciliation of
• • • • • • • • • (1) Non IFRS measure. Refer to page 29 of 2021 Annual Report for reconciliation of Adjusted NPAT to Reported NPAT (2) Key Markets is Victoria, New South Wales, Queensland, South Australia and Northern Territory combined
Slide 8: Chairman's Address
Chairman's Address Thank you The Board wish to thank our investor shareholders for their continued support during the Pandemic; The Company is well positioned to grow earnings in FY22 following strong growth in FY21 notwithstanding challenges presented in certain Markets; | would like to thank our d
Slide 9: CEO Presentation
CEO Presentation Mr. Michael Knaap
Slide 10: Attractive industry fundamentals
Attractive industry fundamentals Advanced maternal age . Advanced maternal age ¢ Behavioural change in the community Innovation/ technology . Growth in service offerings and advances in technology . Stable and continued government funding support Awareness and support e @ Monash IVF Group
Slide 11: Key highlights FY2021
Key highlights FY2021 $23.3m Adjusted NPAT, an increase of 61.5% and ahead of profit guidance * Reported NPAT” of $25.5m, an increase of 116.9% * Adjusted NPAT?2© of $23.3m, an increase of 61.5% and ahead of profit guidance range, ($21m to $23m) * 263% Revenue growth as result of 836.6% stimulated c
Slide 12: MVF Market Share - ARS Australia
MVF Market Share - ARS Australia + MVF Australian FY21 Stimulated Cycles" increased by 36.6% due to Volume Market Share industry growth of 311% and market share gains in MVFs Key markets®). Stimulated Cycles" Key Markets!) Market Share 9 808 Stimulated Cycles?) + MVF Stimulated Cycles" market share
Slide 13: Diagnostic Ultrasound driven by obstetrics growth and shift to privately owned clinics
Diagnostic Ultrasound driven by obstetrics growth and shift to privately owned clinics e FY2021 ultrasound volumes up 12.9% to 92,776 on pep and Non-invasive Pre- natal testing up 17.8% to 15,877; e Despite COVID-19 restrictions, outer suburban ultrasound clinics demonstrated significant growth with
Slide 14: Highly engaged Medical Specialists across Fertility and Ultrasound
ae i Highly engaged Medical Specialists across Fertility and Ultrasound Doctor Partnerships Partnerships and relationships with Monash IVF fertility specialists and Women's Ultrasound sonologists with engagement scores at record levels Five new experienced Fertility Specialists joined Monash IVF to
Slide 15: Clinical pregnancy rates continue to improve
Clinical pregnancy rates continue to improve Pregnancy rates 4.5% higher than CY2018 Initiatives to drive future improvements include: 9 Publication of the first PIEZO clinical trial with continued recruitment of the phase 2 multi- centre clinical trial across 5 Monash IVF sites 9 Sperm selection de
Slide 16: Investment in infrastructure adding capacity and market presence
Investment in infrastructure adding capacity and market presence * New Sydney CBD flagship clinic opened in November 2020 representing best practice patient experience; * The new clinic has performed more than 200 stimulated cycles during FY21 and will improve earnings during FY22; o Transformation
Slide 17: Key stakeholders engaged and supported by significant investments
Key stakeholders engaged and supported by significant investments People Engagement Record Group NPS engagement score in 2021 achieving a “culture of success’, with an increase of 4% points compared to FY20 and exceeded the Vision 2022 target and industry benchmark; The Employer Value proposition is
Slide 18: SE Asian expansion strategy progressing
SE Asian expansion strategy progressing * KL Fertility stimulated cycles increased by 216% compared to FY20 and 2.5% below FY19. Average revenue per stimulated cycle declined by 11% compared to pep due to promotional and discount offerings in-light of competitive pricing pressure and weaker macroeco
Slide 19: MBS items 13200/1 Key Markets is Victoria, New South Wales, Queensland, South Australia and
• • • • • (1) MBS items 13200/1 (2) Key Markets is Victoria, New South Wales, Queensland, South Australia and Northern Territory combined
Slide 20: Our Mission, Our Pillars
Our Mission Our Pillars We help bring ' « = : + life to the world ‘ ais tA Doctor Patient. Scientific People Partnerships Experience Leadership Engagement © @ ® @ International 4 Brand & Clnical ge” Our Outcomes Vision 2026 a + aq ms p> c ‘4 The most admired: reproductive care.” aabreos Siateo = Gee
Slide 21: Strategy & Outlook
Strategy & Outlook The on-going Pandemic has changed the mindset of our patient cohort with greater focus on family, health and wellbeing. This shift has driven strong industry growth in FY2021 and is expected to be maintained in FY2022. Factors that will support future growth includes: * New fertil
Slide 22: Slide 22
Monash IVF Group — Shareholder Meeting (November 2021) on 6ix